Frankfurt
25.07.25 | 08:04
0,078 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,076 | 0,099 | 14:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.07. | Ventripoint Diagnostics Ltd (2): Ventripoint enters term sheet with Lishman for licence | 1 | Stockwatch | ||
| 11.07. | Ventripoint Diagnostics Ltd.: Ventripoint and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology | 2 | TheNewswire | ||
| 11.07. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics 564,473 shares for debt | 1 | Stockwatch | ||
| 30.06. | Ventripoint Diagnostics Ltd (2): Ventripoint to settle debenture interest with shares | 2 | Stockwatch | ||
| VENTRIPOINT DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 30.06. | Ventripoint Diagnostics Ltd.: Ventripoint to Issue Shares for Payment of Debenture Interest | 1 | TheNewswire | ||
| 18.06. | Ventripoint Diagnostics Ltd (2): Ventripoint hires Fournel for advisory services | 1 | Stockwatch | ||
| 17.06. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics grants options | 4 | Stockwatch | ||
| 17.06. | Ventripoint Diagnostics Ltd.: Ventripoint Partners with Fournel Advisory | 2 | TheNewswire | ||
| 17.06. | Ventripoint Diagnostics Ltd.: Ventripoint Issues Option Grants and Reports Exercise of Options | 2 | TheNewswire | ||
| 28.05. | Ventripoint Diagnostics Ltd.: Ventripoint to Exhibit at the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology | 1 | TheNewswire | ||
| 30.04. | Ventripoint Diagnostics Ltd (2): Ventripoint appoints Gall to business advisory board | 1 | Stockwatch | ||
| 30.04. | Ventripoint Diagnostics Ltd.: Ventripoint Expands Advisory Board with addition of Ultrasound AI Executive | 1 | TheNewswire | ||
| 11.04. | Ventripoint Diagnostics Ltd (2): Ventripoint to hold shareholder teleconference April 15 | 1 | Stockwatch | ||
| 10.04. | Ventripoint Diagnostics Ltd.: Ventripoint Provides Corporate Update and Announces Shareholder Teleconference | 1 | TheNewswire | ||
| 08.04. | Ventripoint Diagnostics Ltd (2): Ventripoint $500,000 debenture private placement | 1 | Stockwatch | ||
| 08.04. | Ventripoint Diagnostics Ltd (2): Ventripoint appoints Coutin to oversee clinical affairs | 2 | Stockwatch | ||
| 08.04. | Ventripoint Diagnostics Ltd.: Ventripoint Appoints Nicolas Coutin to Oversee Clinical Affairs | - | TheNewswire | ||
| 08.04. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics warrants extended | 1 | Stockwatch | ||
| 04.04. | Ventripoint Diagnostics Ltd (2): Ventripoint applies to extend 2.84 million warrants | 1 | Stockwatch | ||
| 03.04. | Ventripoint Diagnostics Ltd.: Ventripoint Makes Application to Amend Warrants | 1 | TheNewswire |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS | 0,721 | -1,64 % | Atossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines... ► Artikel lesen | |
| TANDEM DIABETES | 13,330 | +1,41 % | Tandem Diabetes To Pay Roche $36 Mln To Settle Patent Infringement Claim | SOUTH SAN FRANCISCO (dpa-AFX) - Tandem Diabetes Care, Inc. has agreed to pay Roche Holding $36 million over a five year period to settle a patent infringement claim.On May 21, Tandem Diabetes... ► Artikel lesen | |
| NETRAMARK | 0,930 | +2,76 % | Netflix, Netramark, Novo Nordisk - Positive Zeichen | Von wegen: "Sell in may, and go away". Durch die altbekannte Börsenweisheit hätten Anleger im Jahr 2025 so manche Gewinne verpasst. Vielmehr stehen sowohl die global wichtigsten Indizes wie Dow Jones... ► Artikel lesen | |
| VERU | 0,513 | +0,20 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| MOLINA HEALTHCARE | 135,65 | +0,71 % | Molina Healthcare Inc Q2 Profit Drops | WASHINGTON (dpa-AFX) - Molina Healthcare Inc (MOH) released earnings for second quarter that Drops, from the same period last yearThe company's earnings totaled $255 million, or $4.75 per share.... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 2,647 | +1,22 % | TotalEnergies SE - Angola: Start-up of BEGONIA and CLOV Phase 3 Offshore Projects | TotalEnergies announces the start of production from the BEGONIA and CLOV Phase 3 projects, adding a total of 60,000 barrels per day of production offshore Angola. Low cost, low emissions... ► Artikel lesen | |
| COGNETIVITY NEUROSCIENCES | 0,015 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2025ISIN NameCA19243C1005 COGNETIVITY... ► Artikel lesen | |
| SHL TELEMEDICINE | - | - | SHL TELEMEDICINE LTD - 6-K, Report of foreign issuer | ||
| SINTX TECHNOLOGIES | 2,720 | 0,00 % | Sintx Technologies, Inc. - 8-K, Current Report | ||
| SOMNIGROUP INTERNATIONAL | 63,50 | +0,79 % | KeyBanc hebt Kursziel für Somnigroup auf 90 US-Dollar an - Integration von Mattress Firm als Treiber | ||
| SEMLER SCIENTIFIC | 32,200 | -3,01 % | Semler Scientific, Inc. - 8-K, Current Report | ||
| SMILEDIRECTCLUB | - | - | Align Technology Settles Antitrust Lawsuit Over SmileDirectClub Deal for $31.75 Million | ||
| RELEVIUM | 0,013 | -100,00 % | Relevium Technologies Inc.: Relevium Technologies to be delisted from NEX | ||
| NEURONETICS | 3,880 | +2,65 % | Neuronetics Appoints New Chief Financial Officer | Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession... ► Artikel lesen | |
| GENEDX | 81,45 | 0,00 % | Rackspace US, Inc.: Rackspace Technology und Sema4.ai stellen die erste skalierbare KI-Agent-Lösung für Unternehmen vor | Die unternehmensgerechte Lösung schließt die Lücke zwischen KI-Experimenten und umfassender TransformationSAN ANTONIO, June 18, 2025®) und die Anwendungsmanagement-Expertise von Rackspace mit der fortschrittlichen... ► Artikel lesen |
Das Unternehmen VENTRIPOINT DIAGNOSTICS LTD kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,078 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VENTRIPOINT DIAGNOSTICS LTD finden Sie auf Wallstreet Online.